steve fleming
13-07-2013, 12:40 PM
http://www.optiscan.com/default.asp
A global leader in the development and application of microscopic imaging technologies for medical markets (Basically a very miniature microscope that can be used in an endoscope inside the body to be used in neurosurgery, ears, nose and throat surgery (ENT) and spinal surgery etc)
THis allows real time visualisation of tissue at a cellular level leading to improved, earlier, minimally invasive diagnosis and treatment.
A huge amount of research has been undertaken over the last 20 years to develop and commercialise this product.
Now, after 20 years huge amount of R&D, Optiscan is approaching commercial sales with its rigid endomicroscopy system.
FY13 saw the sale of OIL's first pre-production rigid neuro-endomicroscopy systems to Carl Zeiss Meditec (CZM), one of its key development partners and #1 player in the field, (OIL are also partnered with Pentax).
This marks one of the key steps in the path to fully fledged commercial sales in the rigid clinical endomicroscopy space.
As Optiscan sales to CZM grow, the revenue mix will change from the initial systems to be more heavily weighted to disposable and semi-disposable items, with gross margins in excess of 50%.
Current market cap = $11m. (VERSUS THE MORE THAN $95M INVESTED OVER THE LAST 15 YEARS)
As the company says, an opportunity in relation to the market's "Realisation of the distinct company valuation anomaly, lookingforward, not back"
On the verge of commercialisation, all signs suggest that this represents a good opportunity to buy a company that has the opportunity to quickly scale revenues and profits over the next few years, offering a product that has now been accepted by the market and is strong demand.
A global leader in the development and application of microscopic imaging technologies for medical markets (Basically a very miniature microscope that can be used in an endoscope inside the body to be used in neurosurgery, ears, nose and throat surgery (ENT) and spinal surgery etc)
THis allows real time visualisation of tissue at a cellular level leading to improved, earlier, minimally invasive diagnosis and treatment.
A huge amount of research has been undertaken over the last 20 years to develop and commercialise this product.
Now, after 20 years huge amount of R&D, Optiscan is approaching commercial sales with its rigid endomicroscopy system.
FY13 saw the sale of OIL's first pre-production rigid neuro-endomicroscopy systems to Carl Zeiss Meditec (CZM), one of its key development partners and #1 player in the field, (OIL are also partnered with Pentax).
This marks one of the key steps in the path to fully fledged commercial sales in the rigid clinical endomicroscopy space.
As Optiscan sales to CZM grow, the revenue mix will change from the initial systems to be more heavily weighted to disposable and semi-disposable items, with gross margins in excess of 50%.
Current market cap = $11m. (VERSUS THE MORE THAN $95M INVESTED OVER THE LAST 15 YEARS)
As the company says, an opportunity in relation to the market's "Realisation of the distinct company valuation anomaly, lookingforward, not back"
On the verge of commercialisation, all signs suggest that this represents a good opportunity to buy a company that has the opportunity to quickly scale revenues and profits over the next few years, offering a product that has now been accepted by the market and is strong demand.